Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biomark Res
Main Authors: Nie, Yuru, Lu, Weiqing, Chen, Daiyu, Tu, Huilin, Guo, Zhenling, Zhou, Xuan, Li, Meifang, Tu, Sanfang, Li, Yuhua
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254656/
https://ncbi.nlm.nih.gov/pubmed/32514351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00197-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares